DARTISLA ODT

Peak

glycopyrrolate

NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5

Mechanism of Action

Glycopyrrolate, an anticholinergic (antimuscarinic) agent, inhibits the action of acetylcholine on parietal cells in the stomach and decreases the volume and acidity of gastric secretions.

Clinical Trials (5)

NCT07132983Phase 2Completed

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

Started Oct 2025
33 enrolled
Chronic Obstructive Pulmonary Disease
NCT07016412Phase 2Recruiting

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

Started Jul 2025
480 enrolled
Chronic Obstructive Pulmonary Disease
NCT06545500Phase 2Completed

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

Started Aug 2024
46 enrolled
Chronic Obstructive Pulmonary Disease
NCT05887375Phase 4Enrolling By Invitation

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

Started Aug 2023
118 enrolled
Spine SurgeryReversal of Neuromuscular BlockadeUrinary Retention Postoperative
NCT00558285Phase 2Completed

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Started Nov 2007
257 enrolled
Chronic Obstructive Pulmonary Disease (COPD)